These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23013132)

  • 1. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport.
    Yamamoto D; Takai S; Akimoto T; Hirahara I; Ito C; Muto S; Kusano E
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):864-8. PubMed ID: 23013132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
    Yamamoto D; Takai S; Hirahara I; Kusano E
    Clin Chim Acta; 2010 May; 411(9-10):762-4. PubMed ID: 20184869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan.
    Hirahara I; Inoue M; Okuda K; Ando Y; Muto S; Kusano E
    Nephrol Dial Transplant; 2007 Feb; 22(2):560-7. PubMed ID: 17035369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan.
    Hirahara I; Inoue M; Umino T; Saito O; Muto S; Kusano E
    Nephrol Dial Transplant; 2011 May; 26(5):1695-701. PubMed ID: 20921293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
    Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
    Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity.
    Yamamoto D; Takai S; Miyazaki M
    Eur J Pharmacol; 2008 Jul; 588(2-3):277-9. PubMed ID: 18501888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
    Kast RE; Halatsch ME
    Arch Med Res; 2012 Apr; 43(3):243-7. PubMed ID: 22564423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile.
    Yasunari K; Maeda K; Nakamura M; Watanabe T; Yoshikawa J; Asada A
    Cardiovasc Drug Rev; 2004; 22(3):189-98. PubMed ID: 15492767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms.
    Bellini T; Trentini A; Manfrinato MC; Tamborino C; Volta CA; Di Foggia V; Fainardi E; Dallocchio F; Castellazzi M
    J Biochem; 2012 May; 151(5):493-9. PubMed ID: 22343748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
    Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR).
    Ishizuka H; Konno K; Naganuma H; Sasahara K; Kawahara Y; Niinuma K; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1304-11. PubMed ID: 9067317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
    Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
    Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats.
    Hirahara I; Ogawa Y; Kusano E; Asano Y
    Nephrol Dial Transplant; 2004 Jul; 19(7):1732-41. PubMed ID: 15128883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.
    Reinhardt D; Sigusch HH; Hensse J; Tyagi SC; Körfer R; Figulla HR
    Heart; 2002 Nov; 88(5):525-30. PubMed ID: 12381651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ionization state on the activation of temocapril by hCES1: a molecular-dynamics study.
    Vistoli G; Pedretti A; Mazzolari A; Bolchi C; Testa B
    Chem Biodivers; 2009 Nov; 6(11):2092-100. PubMed ID: 19937843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats.
    Nozawa M; Sugimoto K; Ohmori M; Ando H; Fujimura A
    J Pharmacol Exp Ther; 2006 Jan; 316(1):176-81. PubMed ID: 16174798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment.
    Püchler K; Eckl KM; Fritsche L; Renneisen K; Neumayer HH; Sierakowski B; Lavrijssen AT; Thomsen T; Roots I
    Br J Clin Pharmacol; 1997 Dec; 44(6):531-6. PubMed ID: 9431827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemically modified tetracyclines as inhibitors of MMP-2 matrix metalloproteinase: a molecular and structural study.
    Marcial BL; Sousa SF; Barbosa IL; Dos Santos HF; Ramos MJ
    J Phys Chem B; 2012 Nov; 116(46):13644-54. PubMed ID: 23121406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temocapril, an Angiotensin converting enzyme inhibitor, ameliorates age-related increase in carotid arterial stiffness in normotensive subjects.
    Hayashi K; Miyagawa K; Sato K; Ueda R; Dohi Y
    Cardiology; 2006; 106(3):190-4. PubMed ID: 16675905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.